HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
This study preliminarily suggests that the combination of mRNA-HBV-TCR-T cells and lenti-HBV-TCR-T cells could be a safe and potentially effective approach for treating patients following liver transplantation in the context of lifelong immunosuppression drug administration. Further studies are needed to refine treatment strategies and assess long-term safety and efficacy in this special patient population.
Authors
- Weixin Luo (ORCID: https://orcid.org/0009-0002-4587-4329)
- Jiahao Li (ORCID: https://orcid.org/0000-0001-8369-6119)
- Jinbo Huang (ORCID: https://orcid.org/0000-0002-9259-9860)
- Qiang Zhao (ORCID: https://orcid.org/0000-0002-6369-1393)
- Regina Wan Ju Wong
- Xiaoshun He (ORCID: https://orcid.org/0000-0001-5317-9612)
- Jia Dan (ORCID: https://orcid.org/0000-0001-5355-9295)
- Meiting Qin (ORCID: https://orcid.org/0000-0002-5424-1729)
- Tingting Wang
- Sarene Koh
- Zhiyong Guo
- Lu‐En Wai
- Haidong Tan (ORCID: https://orcid.org/0000-0002-1371-9773)
- Zhiying Liu (ORCID: https://orcid.org/0009-0008-8273-9322)
Institutions
- Sun Yat-sen University (CN)
- National University of Singapore (SG)
- China-Japan Friendship Hospital (CN)
- China International Science and Technology Cooperation (CN)
- Key Laboratory of Guangdong Province (CN)
- Red Cross Hospital (GR)
- Deutsche Telekom (Singapore) (SG)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1245
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- Guangdong Special Support Plan